# The Androtriol Injection for the Treatment of Acute Ischemic Stroke

> **NCT06679322** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** Androtriol Injection (High-dose group)
- **DRUG:** Androtriol Injection (Low-dose group)
- **DRUG:** Hydroxypropyl-β-cyclodextrin injection

## Key facts

- **NCT ID:** NCT06679322
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-31
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-10-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06679322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06679322, "The Androtriol Injection for the Treatment of Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT06679322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*